We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

17 hedge funds and large institutions have $12M invested in AEON Biopharma in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.19% less ownership

Funds ownership: 6.99% → 4.8% (-2.2%)

19% less funds holding

Funds holding: 21 → 17 (-4)

39% less capital invested

Capital invested by funds: $19.6M → $12M (-$7.57M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Holders
17
Holders Change
-4
Holders Change %
-19.05%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
7
Calls
$566K
Puts
–
Net Calls
+$566K
Net Calls Change
+$566K

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$110K
2
Walleye Trading
Walleye Trading
New York
+$100K
3
CAC
Cowen and Company
New York
+$97.6K
4
AA
Ancora Advisors
Ohio
+$56.9K
5
Walleye Capital
Walleye Capital
New York
+$21.8K

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$1.59M
2
CCA
Castle Creek Arbitrage
Colorado
-$1.07M
3
SCM
Shaolin Capital Management
Florida
-$1.01M
4
MC
Meteora Capital
Florida
-$811K
5
BFM
Boothbay Fund Management
New York
-$718K

AEON Hedge Fund Activity: Q2 2023 in Review

17 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2023, worth a combined $12M — down 39% from $19.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of AEON and 3 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Clear Street, adding an estimated $110K. The largest seller was Glazer Capital LLC, cutting an estimated $1.59M.

  • 17 institutional investors held AEON Biopharma (AEON) as of Q2 2023, down from 21 in Q1 2023.
  • Funds reported $12M of AEON Biopharma stock for Q2 2023, down 39% quarter-over-quarter.
  • 3 funds opened new AEON Biopharma positions in Q2 2023 and 7 closed out, a net change of -4 holders.
  • The largest AEON Biopharma buyer in Q2 2023 was Clear Street, an estimated $110K added.
  • The largest AEON Biopharma seller in Q2 2023 was Glazer Capital LLC, an estimated $1.59M sold.

Based on aggregated 13F filings for Q2 2023.